-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $18

Benzinga·09/03/2026 15:43:07
语音播报
TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $49 to $18.